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Abstract: The clinical trials of maraviroc showed that treatment failure was mostly associated with lack of X4 virus de-
tection at baseline. The detection limit for X4 in tropism assays is ill defined around 10%. In the current study, quantifica-
tion of X4-tropic minority populations was assessed on artificial mixed samples and 38 clinical isolates. These mixtures 
were subjected to tropism “clonal genotyping” or “population phenotyping”. The detection of minority variants was de-
pendant on the input of amplifiable copies. At VL > 4 log IU/ml, X4 quantification was deemed reliable. PCR founder ef-
fect and clonal resampling might result in misrepresentation of the minority species concentration at VL < 4 log. Fourteen 
of the clinical isolates contained dual/mixed X4-tropic virus, 5 of which were below 10% of the virus population. Cur-
rently, there is no indication what level of X4 would lead to treatment failure. Assays aiming for the detection of minority 
species should express results in function of VL. 
INTRODUCTION 
  Recently, the FDA has approved maraviroc (Selzentry), 
the first of a new class of anti-Human Immunodeficiency 
virus 1 (HIV-1) therapeutics that targets HIV by blocking its 
entry into cells [1]. Maraviroc was approved for use in com-
bination with other antiretroviral drugs in HIV-1 experienced 
adult patients infected with only CCR5-tropic virus. The 
approval of maraviroc is based on safety and effectiveness 
data from 24-week data from two double-blind, placebo-
controlled studies (MOTIVATE 1 and 2) with over 1000 
clinical trial participants [2, 3]. The label indicates that tro-
pism testing and treatment history should guide the use of 
maraviroc, and that the use of maraviroc is not recommended 
in patients with dual/mixed or CXCR4-tropic HIV-1 [4]. 
  A phenotypic tropism test (Trofile, Monogram Bio-
sciences, CA; [5]) was used during the MOTIVATE clinical 
trials to identify patients appropriate for treatment with 
maraviroc. The sensitivity of the Trofile test was determined 
after mixing of molecular clones, not viruses, which revealed 
a 100% sensitivity in picking up 10% X4-variants and 85% 
sensitivity at the 5% level [5]. A total of 50 to 60% of pa-
tients with only R5 viruses were enrolled [2, 3]. Treatment 
failure on maraviroc was associated with detection of 
CXCR4-tropic or dual/mixed tropic virus that was not de-
tected by the tropism assay prior to treatment [4, 6]. As the 
label for maraviroc indicates that prescriptions and use 
should be guided by tropism testing and treatment history, 
and for treatment of CCR5-tropic virus only, the presence of 
X4-tropic virus as detected by assays with cut-offs below 
10% brings a new challenge to the treatment and prescription 
paradigm. 
 
 
*Address correspondence to this author at Virco BVBA, Generaal De Wit-
telaan L11B4, 2800 Mechelen, Belgium; Tel: +32 15 461 486; Fax: +32 15 
285 634; E-mail: ivanden3@vrcbe.jnj.com 
 
§Contributed equally to this work. 
 
  We developed a tropism testing platform including a 
genotypic and phenotypic procedure at a population and 
clonal level [7]. The genotypic and phenotypic assays accept 
amplicons spanning the aminoterminal through the V4-loop 
(NH2-V4) of the HIV-1 Envelope gene. The presence of X4-
tropic virus in the quasispecies in several clinical isolates of 
therapy-naïve individuals was previously illustrated [7]. 
  In the experiments described inhere, we i) further sub-
stantiated the presence of X4-tropic virus at low percentages 
(below 10%) in a random selection of clinical isolates, and 
ii) analyzed simulations of mixed populations at different 
viral loads. 
MATERIALS AND METHODOLOGY 
Sample Selection, and Tropism Determination 
  Properly consented plasma samples (including naïve and 
therapy-experienced) were randomly selected and analyzed 
as described in detail in Van Baelen et al. [7]. In the geno-
typic assay: from 29 (out of 38) clinical isolates a total of 95 
individual clones were analyzed, and an average of 80 ± 7 
(range 62-88, Table 2) clones gave quality approved se-
quences. For the remaining 9 (out of 38) samples, 47 recom-
binant clones were analyzed, resulting in 40 ± 7 (range 23 – 
47, Table 2) sequences useful for tropism prediction using 
PSSM 
(http://ubik.microbiol.washington.edu/computing/pssm/) and 
SVM (http://co-receptor.bioinf.mpi-sb.mpg.de/cgi-bin/co-
receptor.pl). 
Preparation of Plasmids and Recombinant Virus Stocks 
(RVS) 
  The gp120 region from pNL4.3 (X4-tropic; Genbank 
Acc. No. AF324493) or pYK-JRCSF (R5-tropic; Genbank 
Acc. No. M38429) was amplified and cloned into pHXB2D-
NH2-V4-eGFP as described [7]. Recombinant virus stocks 
(RVS) were generated by plasmid nucleofection (Amaxa 
Biosystems, Cologne, Germany) as described [7] except that 
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DNA by washing the cells 16 hours post nucleofection. The 
RVS (referred to as recNL4.3 and recJRCSF) were harvested 
48 hours post-infection. 
Quantification of Viral RNA in RVS 
  Viral load (VL) of recJRCSF and recNL4.3 RVS was 
determined on a 1/10 dilution series using the EasyMAG - 
Nuclisens EasyQ HIV-1 method (Biomérieux, Boxtel, The 
Netherlands). Viral load values obtained were averaged and 
revealed that the recJRCSF RVS and recNL4.3 RVS con-
tained 8.7 +/- 0.16 log IU/ml and 9.4 +/- 0.13 log IU/ml, 
respectively. 
Quantification of Plasmid DNA in RVS 
  The presence of plasmid DNA, relative to the total nu-
cleic acid content, was measured using real-time (RT-)PCR. 
RNA was quantified using primer HIV-1-F (5’-TGGGTTAT 
GAACTCCATCCTGAT-3’), HIV-1-R2 (5’-TGTCATTGA 
CAGTCCAGCTGT-3’) and probe (6-FAM-TTTCTGGCA 
GCACTATAGGCTGTACTGTCCATT-TAMRA). Simi-
larly, DNA was quantified in experiments without reverse 
transcriptase added. recJRCSF and recNL4.3 RVS RNA 
isolates contained 0.31 % and 0.39 % copies plasmid, re-
spectively. 
Preparation of Mixtures of RVS, and RNA Extraction 
  Appropriate amounts of quantified recJRCSF and 
recNL4.3 RVS were used to reconstitute a set of viral mixes 
to yield final recNL4.3 fractions of 2.5% and 1% at 5 log 
IU/ml, 20% and 8% at 4 log IU/ml, and 20% at 3 log IU/ml. 
RNA extraction was performed on 3 to 6 aliquots of 300 l 
each (EasyMAG). 
 
 
Table 1.  Overview of Genotypic and Phenotypic Testing of Artificial Mixed Samples at Various Viral Loads 
 
Sample Characteristics  Clonal Genotype
b E
d Phenotype
 e 
VL (log IU/ml)  # cp in 7x RT-PCR
a  X4 present (%)  # Clones Analyzed  R5 X4 Discordant
c   X4 Measured (%)       
5 17500 2.5 93  91  2  0  2.2  93     
5 17500 2.5 92  90  2  0  2.2  92     
5 17500 2.5 93  93  0  0  0.0  93     
5 17500 2.5 94  94  0  0  0.0  94  R5 
5 17500 2.5 95  91  4  0  4.2  95  D/M 
5 17500 2.5 93  91  2  0  2.2  93  D/M 
5 17500  1  95  95  0  0  0.0  95     
5 17500  1  94  94  0  0  0.0  94     
5 17500  1  94  93  1  0  1.1  94  D/M 
4 1750 20 92  82  10  0  10.9  90    
4 1750 20 93  88  5  0  5.4  91    
4 1750 20 92  85  7  0  7.6  90    
4 1750 20 95  87  8  0  8.4  92  D/M 
4 1750 20 91  78  13  0  14.3  89  D/M 
4 1750 20 94  92  2  0  2.1  92  D/M 
4 1750  8 94  86  8  0  8.5  92    
4 1750  8 95  92  3  0  3.2  92    
4 1750  8 92  85  7  0  7.6  90    
4 1750  8 94  92  2  0  2.1  92    
4 1750  8 92  89  3  0  3.3  90  D/M 
4 1750  8 92  84  8  0  8.7  90  D/M 
3 175 20  95  95  0  0  0.0  73    
3 175 20  89  89  0  0  0.0  70    
3 175 20  90  86  4  0  4.4  71  R5 
3 175 20  94  93  1  0  1.1  73  D/M 
3 175 20  93  49  44  0  47.3  72  D/M 
a Number of viral copies entered in procedure. 
bTropism was inferred from the generated restriction pattern. 
cNumber of discordant clones between PSSM and SVM; all clones were predicted to be R5-tropic in PSSM, but either dual-tropic, X4-tropic or undetermined in SVM. 
dE value obtained from the formula E = D(1-((D-1)/D)
n) representing the expected number of independent clones, n = number of analyzed clones; D = number of input RNA copies. 
Numbers in bold italics indicate conditions where the amount of clones analyzed was greater than the expected number of individual amplifiable genomes present, suggesting resam-
pling conditions. 
ePopulation based phenotypic results obtained on same amplicon used for clonal analysis; D/M: dual tropic or mixed tropic virus population. 10    The Open Virology Journal, 2008, Volume 2  Vandenbroucke et al. 
 
Table 2.  Overview of Genotypic and Phenotypic Testing of 38 HIV-1 Infected Patient Samples at Various Viral Loads 
 
Sample Characteristics  Clonal Genotype
b E
d Phenotype
e 
Sample ID  VL (log IU/ml)  # cp in 7x RT-PCR
a  # Clones Analyzed  R5 X4  Discordant
c   X4 Measured (%)       
1 5.86  126,776  84 0  2  82  2.4  84  R5 
2 5.36  40,250  76 0  2  74  2.6  76  R5 
3 6.58  665,331  86 0  0  86  0.0  86  R5 
4 6.04  192,500  81  54  0  27  0.0  81  R5 
5 5.53  59,500  87  86  0  1  0.0  87  R5 
6 5.26  31,500  78  78  0  0  0.0  78  R5 
7 5.03  18,614  62  11  0  51  0.0  62  R5 
8 5.02  18,200  38  37  0  1  0.0  38  R5 
9 4.93  14,893  41  11  0  30  0.0  41  R5 
10 4.59  6,825  43 20  0  23  0.0 43  R5 
11 4.57  6,550  45 45  0  0  0.0 45  R5 
12 4.34  3,798  40 38  0  2  0.0 40  R5 
13 4.13  2,341  82 81  0  1  0.0 81  R5 
14 3.97  1,624  84  3  0  81  0.0 82  R5 
15 3.90  1,379  38 38  0  0  0.0 37  R5 
16 3.86  1,279  86  0  0  86  0.0 83  R5 
17 3.83  1,183  87  0  0  87  0.0 84  R5 
18 3.81  1,129  84  0  0  84  0.0 81  R5 
19 3.31  361  88  0  0  88  0.0 78  R5 
20 3.29  343  44  0  0  44  0.0 41  R5 
21 2.71  90  62  0  0  62  0.0 45  R5 
22 2.48  53  81 79  0  2  0.0 42  R5 
23 2.47  52  47  0  0  47  0.0 31  R5 
24 2.14  24  87  0  0  87  0.0 24  R5 
25 6.23  297,500  71  2  7  62  9.9 71  D/M 
26 6.15  245,000  71  0  5  66  7.0 71  D/M 
27 6.11  227,500  76  1  7  68  9.2 76  D/M 
28 5.90  140,000  76  0  10  66  13.2  76  D/M 
29 5.83  118,315  83  0  12  71  14.5  83  D/M 
30 5.82  115,621  85  0  23  62  27.1  85  D/M 
31 5.41  44,982  86  0  11  75  12.8  86  D/M 
32 5.20  28,000  76  0  3  73  3.9 76  D/M 
33 5.18  26,250  84  0  1  83  1.2 84  D/M 
34 4.91  14,225  86  0  10  76  11.6  86  D/M 
35 4.43  4,710  76 12  64  0  84.2  75  D/M 
36 2.92  146  87 30  57  0  65.5  66  D/M 
37 2.66  79  23 20  0  3  0.0 20  D/M 
38 2.19  27  86  0  84  2  97.7  26  D/M 
aNumber of viral copies entered in procedure. 
bTropism determination by clonal genotyping. Prediction was performed on the clonal V3 loop sequences using the PSSM and SVM on-line available software 
cNumber of discordant clones between PSSM and SVM; all clones were predicted to be R5-tropic in PSSM, but either dual-tropic, X4-tropic or undetermined in SVM. 
dE value obtained from the formula E = D(1-((D-1)/D)
n) representing the expected number of independent clones, n = number of analyzed clones; D = number of input RNA copies. 
Numbers in bold italics indicate conditions where the amount of clones analyzed was greater than the expected number of individual amplifiable genomes present, suggesting resam-
pling conditions. 
ePopulation based phenotypic results obtained on same amplicon used for clonal analysis; D/M: dual tropic or mixed tropic virus population. 
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Restriction Analysis 
 AluI restriction digestion was performed on the colony 
PCR products in order to distinguish between clones from 
recNL4.3 (4 fragments) or recJRCSF (3 fragments). 
RESULTS 
Tropism Analysis of Reconstituted Samples According to 
Viral Load 
  Since the exact composition of the viral quasispecies in 
clinical isolates is unknown, we aimed to mimic minority 
species conditions on artificial lab-generated virus mixtures. 
  The theoretical number of recNL4.3 copies, present in 
each RT-PCR reaction was calculated for different viral 
loads, and plotted as a function of the fraction recNL4.3 in 
the original viral mixture (Fig. 1). From this Figure one can 
deduce that, if, for example, the extraction/ amplification 
procedure starts with 300 μl plasma, eluted in 60 μl H2O, of 
which 5 μl is used in RT-PCR, the 20% minority fraction at 
3 log IU/ml corresponds to only 5 copies. Hence, the ability 
to detect minority quasispecies depends on initial viral load 
and assay design (amount of RNA copies used for RT-PCR). 
  Subsequently, artificial viral mixtures panels were ana-
lyzed as visualized in Fig. (2), and results are shown in Table 
1. At 5 log IU/ml, a 1% minority variant was detected in one 
out of three repeat experiments, while a 2.5% minority vari-
ant was detected in four out of six repeat experiments. At 4 
log IU/ml, the minority detection success rate was 6 out of 6 
(100%) for an 8% and 20% minority population. At 3 log 
IU/ml, the 20% minority variant was detected in three out of 
five experiments. At 5 and 4 log IU/ml, fluctuations between 
the different outcomes of the parallel experiments were rela-
tively low, while at 3 log IU/ml, detected quantities were 
very different and varied from 0 to 47.3%. This can be as-
 
Fig. (1). Visualization of the theoretical number of copies of recNL4.3 in each RT-PCR reaction. X-axis: percentage of the minority species 
recNL4.3 in the total amount of amplifiable RNA genomes; Y-axis: number of copies of the minority species per RT-PCR reaction. The 
number of copies per reaction is function of the viral load and experimental procedure. Dashed line: 5 log VL; dotted line: 4 log VL; solid 
line: 3 log VL. Experimental conditions (viral load, sample amount in RNA extraction, RNA input in RT-PCR) influence the slope of the 
lines. This figure represents the applied conditions. 
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cribed to the initial founder effect in PCR reactions with low 
copy numbers, and visualized/enhanced by resampling dur-
ing colony picking. When analyzing n random amplification 
products from an RT-PCR performed with a sample contain-
ing D RNA molecules, the expected number of independent 
clones (E) is given by E = D(1-((D-1)/D)
n) [8, 9]. For exam-
ple at 3 log IU/ml, 175 RNA copies (= D) were inserted into 
the RT-PCR and 93 clones were picked (= n), hence E = 
175(1-((175-1)/175)
93) = 72. Applied to our experimental 
conditions, resampling might occur at a viral load of ap-
proximately 4 log or less. A selection of the samples was 
also tested in the population-based phenotypic analysis. At 5 
log IU/ml, a 1% X4-tropic minority species was detected 
(Table  1). In the 2.5% recNL4.3 experiment in which no 
recNL4.3 could be detected genotypically, there was also no 
X4-tropic virus detected by phenotypically. At 4 log IU/ml, 
the minority species were detected in all experiments; at 3 
logIU/ml, the minority was detected in two out of three ex-
periments. 
  From these experiments the following conclusions were 
 
Fig. (2). Workflow for genotypic and phenotypic analysis of the recJRCSF/recNL4.3 mixtures. Two RVS were mixed at different ratios and 
viral loads. Each mixture was split into 6 aliquots and processed in parallel. RNA was extracted of each aliquot, followed by 7 replicate am-
plifications of the NH2-V4 region. PCR products were pooled, purified and cloned. Colonies were picked, the insert was PCR amplified, 
purified and analyzed by AluI restriction analysis. Tropism was assessed by population-based phenotyping as described [7]. Infection of 
CCR5- and CXCR4-expressing U87-cells was scored using a fluorescent microscope and FACS. 
GENOTYPING
recJRCSF RVS recNL4.3 RVS
Mixture at different VL and recNL4.3/recJRCSF ratio
RNA extraction on 6 aliqouts
Replicate (7×) RT-PCR on each aliqout
Pool and purify replicate amplicons
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made: i) qualitative detection of the minority species of the 
total population is possible genotypically and phenotypically 
between 3 to 5 log IU/ml; ii) quantification of the minority 
species is possible genotypically, but only if the viral load is 
higher than 4 log IU/ml, and it requires multiple separate 
amplifications and a high amount of colonies to analyze (Ta-
ble 1); iii) quantification of the minority species in samples 
with a viral load below 4 log IU/ml is technically challeng-
ing and it might contain the bias of founder effect amplifica-
tion (PCR drift). 
Tropism Analysis of Clinical Samples 
  With the availability of genotyping and phenotyping pro-
tocols – including a minority species quantification if viral 
load is > 4 log of IU/ml in the genotypic assay - a total of 38 
random clinical samples were analyzed (Table 2). In 39% of 
the samples (15/38), both algorithms predicted the presence 
of X4, of which 7 (47%) had X4 frequencies below 10%, 
and 4 samples (27%) below 5%. Five out of the 7 samples 
with X4 virus below 10% (samples 25, 26, 27, 32 and 33) 
were resulting in the population–based phenotyping as 
dual/mixed tropic (D/M) virus. Two samples that contained a 
subpopulation of X4 predicted clones at ± 2.5% (samples 1 
and 2) resulted in the phenotypic assay as R5-tropic only. 
From another 19 samples, clonal sequences with discordant 
predictions were obtained, but all of these belonged to sam-
ples that were phenotypically R5-only. One sample con-
tained D/M virus (sample 37), which could not be detected 
using genotypic analysis. 
  The formula E = D(1-((D-1)/D)
n) [8, 9] was also applied 
to these experiments (Table 2), again illustrating that resam-
pling occurred at a viral load of approximately 4 log or less. 
Especially in the D/M samples with low copy number input, 
PCR founder effects and resampling could bias the results 
and might lead to high percentages of X4 clonal sequences. 
Also, the detection of the minor percentages of X4 tropic 
virus was only in samples with a viral load higher than 4 log 
IU/ml. 
  The conclusions of these experiments were as follows: i) 
X4 tropic virus is often present in clinical isolates at low 
percentages (<10% of the total population) and might remain 
undetected in some routine diagnostic tests; ii) below 4 log 
IU/ml, genotypic results are qualitative; iii) the qualitative 
phenotypic assay applied in these experiments detects most 
of the X4 predicted genotypes; and iv) several hundreds of 
genotypic clones were found discordant in the prediction 
algorithms (as was also recently described [10]). 
DISCUSSION 
  CCR5 antagonists belong to the co-receptor antagonist 
drug class. Maraviroc, also known as Selzentry or Celsentri, 
is the first to receive accelerated approval by the FDA for 
use in combination therapy in adults infected with only 
CCR5-tropic HIV-1. Clinical resistance to maraviroc has not 
yet been fully defined, but virologic failure has been associ-
ated with the unmasking of X4-tropic virus by reducing the 
R5-tropic majority population, currently also interpreted as 
viral tropism switches [4]. The FDA states that screening for 
X4 viruses by HIV-1 tropism testing prior to therapy with a 
coreceptor antagonist should guide the use of maraviroc [4]. 
Several assays are available (commercially and non-
commercially) that determine coreceptor usage. Some of 
these are based on genotypic analysis of (parts of) the enve-
lope gene, which are either sequenced and interpreted with 
an algorithm [7, 11], or tropism detection is based on differ-
ential hybridization of an amplicon to a probe set [12, 13]. 
Genotypic assays are generally fast and cheap. They rely 
however on the current knowledge about mutations and po-
lymorphisms associated with co-receptor usage (interpreta-
tion algorithms or reference DNA probes). As the correlative 
databases will increase and algorithms will be improved, 
these methods might gain in importance. Phenotypic meth-
ods are based on viral entry into host cells either containing 
the CCR5 or CXCR4 co-receptor. Recombinant viruses are 
prepared by cloning or recombining (part of) the envelope 
gene into an HIV-1 backbone deleted for the corresponding 
amplicon. They consist either of a single-cycle assay (Trofile 
and Phenoscript [5, 14, 15] or multiple cycle assay (PhenXR 
and Antivirogram [7, 12]). The limit of detection for X4-
virus in the single cycle assays is around 5-10% [5, 16]. It is 
not clear what level of X4-tropic virus would lead to treat-
ment failure and what degree of X4 increase is reason for 
concern. 
  Sensitivity of an assay towards detection of a minor 
population is assessed in some studies by analyzing mixtures 
of amplicons [17] or plasmids [5, 18]. Extraction and ampli-
fication of viral RNA was not included in such evaluations, 
although these steps are an integral part of the assay 
workflow and contribute crucially and significantly to its 
sensitivity. We mimicked clinical isolates by mixing an X4-
tropic minority variant with R5 tropic virus at different viral 
loads. The proportion of minority variants that can be de-
tected is inversely proportional to the viral load of the sam-
ple, as theoretically anticipated [19]. It might be unrealistic 
to expect detection of minority variants below 1% at 5 log 
IU/ml, with decreasing chance of success at even lower viral 
load. 
  At 3 log IU/ml, and a 20% minority component, expected 
vs measured outcomes differed severely. This bias in tem-
plate-to-product ratio is known as PCR drift and is caused by 
stochastic variation in the early cycles of the reaction, lead-
ing to a deviating estimation of the template frequency, es-
pecially at low copy numbers [20, 21]. In addition, the calcu-
lated number of copies present in the sample might be sub-
stantially lower than measured by the VL assay, which is 
based on amplification of a very small fragment (± 80 bp). In 
contrast, the amplification of the longer NH2-V4 fragment (± 
1,3 Kb) is much more dependent on the presence of intact 
RNA. 
  A second problem at low viral load might be the issue of 
resampling [9]. Resampling occurs if one or only a few 
molecules of the sample are used as input for the PCR and 
results in repeated analysis of PCR products amplified from 
the same amplifiable viral RNA molecule. This can result in 
artificially low levels of viral diversity, not representative for 
the original sample. To avoid resampling, the maximal 
amount of analyzed clones should not exceed the number of 
inserted copies into the RT-PCR [8, 9]. 
  There is growing evidence that minor X4 subpopulations 
are common among HIV-1 patients [22, 23]. As viral tro-
pism determination assays will become more mature and 
more sensitive, X4-tropic virus will be detected in many 14    The Open Virology Journal, 2008, Volume 2  Vandenbroucke et al. 
more patients samples. It needs to be determined what the 
clinical significance of these populations is and what the 
implications are for co-receptor antagonist use. Our results 
show the quantification limitations in PCR technologies on 
samples with a low amount of amplifiable genomes. This 
phenomenon is inherent to all PCR-based assays (including 
testing for protease and RT gene resistance mutations) on 
small amounts of complex templates [24] and should be 
carefully considered when samples are analyzed with low 
input copy number. Assays aiming for minority species de-
tection are limited by the amount of copies inserted into the 
RT-PCR procedure and should express results in function of 
the number of target molecules present in the original sam-
ple. 
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